secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001549084-23-000057
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics Q2 2023 record revenue $4.7M, up 36% YoY; net loss $0.31/share
---------------------------------------------------------------------------

- Revenue $4.7M (+36% YoY); gross profit $2.3M (48% margin) vs $1.6M (47%) in Q2 2022.
- Net loss $4.2M ($0.31 diluted EPS) vs $3.0M ($0.23) a year ago, driven by HMC acquisition costs.
- Booked 44 EksoHealth devices in Q2; cash $13.3M at June 30, 2023 versus $20.5M at Dec 31, 2022.
- Sales & marketing $2.3M, R&D $1.4M, G&A $2.8M; all up YoY due to HMC integration and severance.
- Six-month 2023 revenue $8.8M (+46% YoY); net loss $8.6M compared to $7.6M in H1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000154908423000057/0001549084-23-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000154908423000057/ekso-20230727.htm
  HTML page:      https://secwatch.observer/filing/0001549084-23-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer